Urgent Investor Alert

Gentle, Radiation-Free Cancer-Detection Breakthrough—
An Investor’s Dream

	Ian Wyatt, one of America’s top growth stock experts, is editor and publisher of the new Rising Star Stocks newsletter, which uses a method he developed, the Early Growth Indicator (EGI) System, to focus on up-and-coming small and micro cap stocks. He is also the editor and publisher of the Growth Report, a leading independent growth stock investment newsletter that posted returns of 26% in 2001, 40% in 2002 and 52% in 2003 for its subscribers. DOBI Medical International, Inc. Symbol: OTCBB: DBMI Price Target: $6.00 Rating: BUY Please note: This is an aggressive opportunity. For more detailed information about DOBI Medical International, please visit my website at http://www.earlyprofits.com/.    As one of America’s top growth stock experts, Ian Wyatt is recommending that his subscribers buy this stock as a long-term investment.

    Every 12 minutes, a woman dies from breast cancer. But when this revolutionary technology hits the market, breast cancer can be detected years earlier, potentially saving lives and producing record profits for investors. Don’t miss your chance to…

    Turn a $5,000 investment into $13,333 in 12 to 18 months!

    If you buy only one medical technology stock this year, then this company should be near the top of your prospective list.

Dear Investor,

    Let me tell you about a cancer-detection breakthrough that could make investors very wealthy.

    Not only could this company deliver profits of up to 167% in the next 12 to 18 months, but it could also dramatically change breast cancer detection for the better.

    That’s because the medical imaging system it produces has the potential to diagnose breast cancer five to eight years sooner than mammograms.

    It’s no surprise then that DOBI Medical International already has its first international sales agreement in place to sell 40 of these systems in the next 18 months, and based on an expected unit price of $140,000, should generate an incredible $5.6 million in unit sales for the company!

    So how did I come across such a rich opportunity to profit? I simply used…

MY PROVEN SYSTEM FOR SPOTTING SUPER-GROWTH STOCKS

    I call it my Early Growth Indicator (EGI) System, and I developed it as a way to locate and evaluate companies that are on the upswing…long before Wall Street catches wind of them.

    Using all the research and insights that I collected for the Growth Report, my first newsletter, I am able to apply core research measures to companies at an even earlier stage. These indicators help me determine whether a company will go boom or bust in the months and years to come.

    Based on my successful track record in finding these ultra-growth opportunities, I believe DOBI could very well be my next Rising Star stock.

    Just take a look at the extraordinary profits my previous picks have produced:

   •  Sonic Solutions shot up 477% in 32 months!
   •  j2 Global Communications surged 360% in 24 months!
   •  Lexar Media skyrocketed 444% in 12 months!

    Of course, even as an early-stage medical technology company in the final phase of FDA approval, DOBI should be considered a more aggressive investment, and as such, comes with a higher degree of risk. Yet the potential rewards are phenomenal!

A MIRACULOUS BREAKTHROUGH IN BREAST CANCER DIAGNOSIS

    A technology-based medical device company, DOBI Medical International, Inc. (OTCBB: DBMI) has developed a unique, gentle, radiation-free and economical way to identify new blood vessel growth—or angiogenesis—a key element in cancer detection.

    As an adjunct to mammography, the DOBI ComfortScan™ System has the potential to provide many improvements over currently available imaging technologies in a variety of areas—accuracy, speed, comfort, safety, convenience, ease of use and low scan cost.

    With final approval hoped for from the U.S. Food and Drug Administration in late 2005, this dynamic optical breast imaging (DOBI) system could result in significant cost savings.

    That’s because this noninvasive breast cancer detection procedure will cost only a fraction of what doctors and hospitals charge to perform a routine biopsy and should also reduce the number of needless biopsies.

WHEN IT COMES TO FUTURE GROWTH, THE SKY’S THE LIMIT

    With everything I know about this medical technology company, I believe it’s positioned to take advantage of the spectacular growth opportunities in the medical imaging market, which could result in enormous profits for both the Company and its investors.

    That’s why I strongly encourage you to take an in-depth look at DOBI Medical International by visiting http://www.earlyprofits.com/ right now. Not only will you learn more about this up-and-coming stock, you’ll also find out how to regularly receive other Rising Star Stocks recommendations like this.

    By following my recommendations on this stock, you could soon see profits of up to 167% or more. And that means a $10,000 investment could easily skyrocket to $26,666!

    To invest in DOBI Medical International, Inc. (OTCBB: DBMI) now, go online or contact your discount broker.

Happy Investing,

Ian Wyatt
Editor & Publisher

P.S. Discover how you can receive up to 5 valuable investment reports valued
at $145—FREE—by visiting http://www.earlyprofits.com/.

Rising Star Stocks
611 Pennsylvania Avenue SE, #417
Washington, DC 20003

For subscription information, visit our website at http://www.earlyprofits.com/.

Or call Toll-Free 1-800-368-7291,
24 hours a day, 7 days a week

Rising Star Stocks is an independent paid circulation newsletter. This online report and the opinions of those quoted herein are for informational and advertising purposes only. No statement or expression of opinion is a direct or indirect offer or a solicitation of any offer to buy or sell securities. All information used to prepare this report is believed to be from reliable sources, but makes no representation that such information is, in fact, reliable or accurate. The information and conclusions contained in this issue meet the same review standards as those for other scheduled issues of Rising Star Stocks. Ian Wyatt and the Rising Star Stocks newsletter received no stock or compensation with respect to the writing of this report. Rising Star Stocks expects to generate new subscriber revenue, the amount of which is unknown at this time, to its newsletter through the online distribution of this report. Ian Wyatt, publisher of the Rising Star Stocks newsletter, certifies that the views expressed in this report accurately reflect his personal views; and that no part of distribution to potential subscribers was, is, or will be directly or indirectly related to specific recommendations. Any opinions expressed in this report are subject to change without notice. Any forecasts contained in this report were independently prepared, unless otherwise stated, and have not been endorsed by the management of the company that is the subject of this report. Rising Star Stocks does not inform any featured company in advance of the conclusions of any report in advance of dissemination to its subscribers and/or public.

Strategic Initiatives Inc. was retained by DOBI Medical International, Inc. to develop public recognition of and interest in DOBI Medical International, Inc. Strategic Initiatives Inc. administered a budget, provided by DOBI Medical International, Inc., in an effort to develop and execute a Public Awareness Plan. As part of this plan, Strategic Initiatives Inc. paid $80,500 to marketing vendors, which was used to pay for all the costs of distributing this report online. Rising Star Stocks and DOBI Medical International, Inc. are separate businesses and not affiliated with each other, either directly or indirectly. DOBI Medical International, Inc. has granted Strategic Initiatives Inc. an option to acquire up to 250,000 shares of DOBI Medical International, Inc. common stock at an exercise price of $1.54 per share. Strategic Initiatives Inc. and/or its affiliates also own 475,000 freely tradable shares of DOBI Medical International, Inc. common stock representing approximately 1.3% of the issued and outstanding voting capital of the company. As of July 15, 2004, Ian Wyatt owned 0 shares of DOBI Medical International, Inc. common stock, and he will not buy, sell or offer to sell any shares of such stock for 90 days after the date of distribution of this report. Readers should also consider this report as only a single factor in making any investment decision.

Rising Star Stocks may, from time to time, feature emerging growth companies whose securities typically involve a higher degree of risk and more volatility than securities of more established companies. Speculation in securities carries a high degree of risk and investors purchasing speculative investments should be capable of absorbing losses of all their invested capital. There is no assurance that the companies mentioned in this report will receive additional funding or experience any future development necessary for corporate success. Income from investments may fluctuate. The price or value of the investments to which this publication relates, either directly or indirectly, may rise or fall against the interest of investors. Any estimates of future returns are based on assumptions that may not be realized and are not intended to predict performance of any investment.

Ian Wyatt and the Rising Star Stocks newsletter are not registered investment advisors. Nothing in this report is intended to be, and should not be considered as, investment advice. Investments and strategies discussed or recommended in this report may be unsuitable for investors, depending on their specific investment objectives and financial position. Readers interested in purchasing securities of the company featured in this report are encouraged to consult with their investment advisors. Past investment performance is not in any way indicative of future investment performance. This publication does not provide an analysis of the company’s financial position. Readers must also independently verify all information herein. Readers are strongly recommended to read and evaluate DOBI Medical International, Inc.’s press releases and filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-KSB/A for the fiscal year ended December 31, 2003 and its Quarterly Report on Form 10-QSB for the quarter ended March 31, 2004. This report is not intended for readers resident in a jurisdiction where such reports are not permissible under local regulations, and investors in those jurisdictions should disregard it. Readers must also independently verify “blue sky eligibility” of any securities mentioned with this report. Complete investor information, including information about the status of public company registrations and filings and other investor resources can be found at the Securities and Exchange Commission website at http://www.sec.gov/.

This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Ian Wyatt and Rising Star Stocks.